Compugen Stock Today
| CGEN Stock | USD 1.54 0.02 1.32% |
PerformanceSoft
| Odds Of DistressLow
|
Compugen is selling at 1.54 as of the 29th of December 2025; that is 1.32% increase since the beginning of the trading day. The stock's open price was 1.52. Compugen has only a 8 % chance of going through financial distress over the next few years but had a somewhat soft performance during the last 90 days. The performance scores are derived for the period starting the 29th of November 2025 and ending today, the 29th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of August 2000 | Category Healthcare | Classification Health Care |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. The company has 93.54 M outstanding shares of which 941.81 K shares are currently shorted by private and institutional investors with about 3.14 trading days to cover. More on Compugen
Moving against Compugen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Compugen Stock Highlights
| President CEO, Director | Anat CohenDayag | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCompugen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Compugen's financial leverage. It provides some insight into what part of Compugen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compugen (CGEN) is traded on NASDAQ Exchange in USA and employs 74 people. Compugen is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 144.96 M. Compugen conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 93.54 M outstanding shares of which 941.81 K shares are currently shorted by private and institutional investors with about 3.14 trading days to cover.
Compugen currently holds about 88.21 M in cash with 49.6 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02.
Check Compugen Probability Of Bankruptcy
Ownership AllocationCompugen holds a total of 93.54 Million outstanding shares. Almost 84.32 percent of Compugen outstanding shares are held by general public with 2.02 (percent) owned by insiders and only 13.66 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Compugen Ownership Details
Compugen Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Compugen market risk premium is the additional return an investor will receive from holding Compugen long position in a well-diversified portfolio.
| Mean Deviation | 3.3 | |||
| Semi Deviation | 3.13 | |||
| Standard Deviation | 4.69 | |||
| Variance | 21.97 |
Compugen Stock Against Markets
Compugen Corporate Management
| Zurit Levine | VP of Research and Discovery | Profile | |
| Alberto Sessa | Chief Officer | Profile | |
| Rivka Schwartz | Vice Discovery | Profile | |
| Henry MD | Senior Officer | Profile | |
| Eran Ophir | Chief Officer | Profile | |
| Michelle MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Compugen Stock, please use our How to Invest in Compugen guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compugen. If investors know Compugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Compugen is measured differently than its book value, which is the value of Compugen that is recorded on the company's balance sheet. Investors also form their own opinion of Compugen's value that differs from its market value or its book value, called intrinsic value, which is Compugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compugen's market value can be influenced by many factors that don't directly affect Compugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.